PSP Research LLC Buys New Position in NewAmsterdam Pharma Company N.V. $NAMS

PSP Research LLC bought a new stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) during the fourth quarter, HoldingsChannel.com reports. The fund bought 14,920 shares of the company’s stock, valued at approximately $523,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Atle Fund Management AB raised its position in NewAmsterdam Pharma by 1.8% in the 4th quarter. Atle Fund Management AB now owns 197,036 shares of the company’s stock valued at $6,912,000 after buying an additional 3,411 shares during the last quarter. Handelsbanken Fonder AB raised its position in NewAmsterdam Pharma by 2.5% in the 4th quarter. Handelsbanken Fonder AB now owns 415,800 shares of the company’s stock valued at $14,586,000 after buying an additional 10,000 shares during the last quarter. DNB Asset Management AS acquired a new stake in NewAmsterdam Pharma in the 4th quarter valued at approximately $706,000. Navalign LLC acquired a new stake in NewAmsterdam Pharma in the 4th quarter valued at approximately $46,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in NewAmsterdam Pharma in the fourth quarter valued at approximately $253,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

Analysts Set New Price Targets

NAMS has been the subject of a number of analyst reports. HC Wainwright upgraded NewAmsterdam Pharma to a “strong-buy” rating in a research note on Thursday, February 19th. Guggenheim raised their price target on NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a research note on Thursday, February 19th. Needham & Company LLC raised their price target on NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Finally, Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, NewAmsterdam Pharma has a consensus rating of “Moderate Buy” and a consensus target price of $48.00.

NewAmsterdam Pharma Stock Down 1.2%

NAMS opened at $33.72 on Wednesday. NewAmsterdam Pharma Company N.V. has a 12-month low of $16.78 and a 12-month high of $42.21. The stock has a market cap of $3.94 billion, a price-to-earnings ratio of -18.84 and a beta of 0.02. The business has a 50 day moving average of $32.49 and a 200-day moving average of $34.28.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The business had revenue of $3.04 million during the quarter. As a group, analysts expect that NewAmsterdam Pharma Company N.V. will post -1.76 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Michael H. Davidson sold 443,707 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $33.25, for a total transaction of $14,753,257.75. Following the completion of the sale, the chief executive officer directly owned 174,144 shares of the company’s stock, valued at approximately $5,790,288. This trade represents a 71.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Johannes Jacob Piete Kastelein sold 101,409 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $30.29, for a total value of $3,071,678.61. Following the sale, the insider directly owned 69,302 shares of the company’s stock, valued at approximately $2,099,157.58. The trade was a 59.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 1,168,286 shares of company stock valued at $38,211,967. Insiders own 12.74% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.